Skuldtech Readies Companion Diagnostic for TKI Masitinib
By Cormac Sheridan
Tuesday, November 6, 2012
French diagnostics firm Skuldtech SAS has emerged as the company behind a phenotypic biomarker that offers a simple predictive indication of which pancreatic cancer patients will benefit from an investigational tyrosine kinase inhibitor (TKI) currently under regulatory review in Europe.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.